These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38595721)

  • 1. Anticancer potential of novel symmetrical and asymmetrical dihydropyridines against breast cancer
    Faizan S; Talath S; Wali AF; Hani U; Haider N; Mandal SP; Kumar BRP
    RSC Adv; 2024 Apr; 14(16):11368-11387. PubMed ID: 38595721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel thiophene Chalcones-Coumarin as acetylcholinesterase inhibitors: Design, synthesis, biological evaluation, molecular docking, ADMET prediction and molecular dynamics simulation.
    Hasan AH; Murugesan S; Amran SI; Chander S; Alanazi MM; Hadda TB; Shakya S; Pratama MRF; Das B; Biswas S; Jamalis J
    Bioorg Chem; 2022 Feb; 119():105572. PubMed ID: 34971946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR
    Raghunath Khedkar N; Sindkhedkar M; Joseph A
    Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
    Shaheen MA; El-Emam AA; El-Gohary NS
    Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFR
    Aljohani AKB; El-Adl K; Almohaywi B; Alatawi OM; Alsulaimany M; El-Morsy A; Almadani SA; Alharbi HY; Aljohani MS; Abdulhaleem M FA; Osman HEM; Mohamady S
    RSC Adv; 2024 Mar; 14(12):7964-7980. PubMed ID: 38454937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors.
    Farouk AKBAW; Abdelrasheed Allam H; Rashwan E; George RF; Abbas SE
    Bioorg Chem; 2022 Nov; 128():106099. PubMed ID: 35994884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring pyrrolidinyl-spirooxindole natural products as promising platforms for the synthesis of novel spirooxindoles as EGFR/CDK2 inhibitors for halting breast cancer cells.
    Nafie MS; Al-Majid AM; Ali M; Alayyaf AA; Haukka M; Ashraf S; Ul-Haq Z; El-Faham A; Barakat A
    Front Chem; 2024; 12():1364378. PubMed ID: 38487783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical Characterization,
    Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
    Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new class of anti-proliferative activity and apoptotic inducer with molecular docking studies for a novel of 1,3-dithiolo[4,5-
    Ismail MA; Abusaif MS; El-Gaby MSA; Ammar YA; Ragab A
    RSC Adv; 2023 Apr; 13(18):12589-12608. PubMed ID: 37101951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel quinoxaline derivatives as dual EGFR and COX-2 inhibitors: synthesis, molecular docking and biological evaluation as potential anticancer and anti-inflammatory agents.
    Ahmed EA; Mohamed MFA; Omran OA
    RSC Adv; 2022 Sep; 12(39):25204-25216. PubMed ID: 36199335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of 2-amino-4,6-diarylpyrimidine derivatives as potent α-glucosidase and α-amylase inhibitors: structure-activity relationship,
    Mughal EU; Amjid S; Sadiq A; Naeem N; Nazir Y; Alrafai HA; Hassan AA; Al-Nami SY; Abdel Hafez AA; Ali Shah SW; Ghias M
    J Biomol Struct Dyn; 2024; 42(1):244-260. PubMed ID: 37096830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR.
    Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A
    Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study.
    Fakhry MM; Mattar AA; Alsulaimany M; Al-Olayan EM; Al-Rashood ST; Abdel-Aziz HA
    Molecules; 2023 Nov; 28(21):. PubMed ID: 37959874
    [No Abstract]   [Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: In vitro screening and ADME predictions.
    Kardile RA; Sarkate AP; Lokwani DK; Tiwari SV; Azad R; Thopate SR
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114889. PubMed ID: 36375337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Preclinical Evaluation of Indole Triazole Conjugates as Microtubule Targeting Agents that are Effective against MCF-7 Breast Cancer Cell Lines.
    Yele V; Pindiprolu SKSS; Sana S; Ramamurty DSVNM; Madasi JRK; Vadlamani S
    Anticancer Agents Med Chem; 2021; 21(8):1047-1055. PubMed ID: 32981511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro and In Silico Evaluation of Antiproliferative Activity of New Isoxazolidine Derivatives Targeting EGFR: Design, Synthesis, Cell Cycle Analysis, and Apoptotic Inducers.
    Alminderej F; Ghannay S; Omer Elsamani M; Alhawday F; Albadri AEAE; Elbehairi SEI; Alfaifi MY; Kadri A; Aouadi K
    Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iodoquinazoline-derived VEGFR-2 and EGFR
    Mohamed AA; El-Hddad SSA; Aljohani AKB; Khedr F; Alatawi OM; Keshek DE; Ahmed S; Alsulaimany M; Almadani SA; El-Adl K; Hanafy NS
    Bioorg Chem; 2024 Feb; 143():107062. PubMed ID: 38150938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the interaction between epidermal growth factor receptor tyrosine kinase and some of the synthesized inhibitors using combination of
    Nasab RR; Mansourian M; Hassanzadeh F; Shahlaei M
    Res Pharm Sci; 2018 Dec; 13(6):509-522. PubMed ID: 30607149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.